Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.

Baricitinib is the most effective treatment for alopecia areata.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

High-dose vitamin D and an anti-inflammatory diet may help improve symptoms in autoimmune conditions like SLE and AA.

Apremilast did not work for treating severe alopecia areata.

Experts recommend starting systemic treatment for alopecia areata when the condition is severe or causes significant distress.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Alopecia areata significantly affects emotional well-being and daily activities, suggesting a need for patient-centered care.

The document's conclusion cannot be provided because the content is not accessible.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

Tofacitinib treatment for hair loss may worsen acne.

Dexamethasone oral mini-pulse therapy effectively treats severe alopecia areata when JAK inhibitors can't be used.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Eczema patients have a lower skin lipid to protein ratio, older and longer-staying hospital patients are more likely to get pressure ulcers, hair loss in AGA is linked to muscle degeneration, vitamin D deficiency is common in alopecia areata and linked to its severity, standard liver tests don't effectively detect fibrosis in psoriasis patients on methotrexate, and bullous pemphigoid patients have a higher death risk but combination therapy may reduce it.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

Baricitinib works better than methotrexate for severe alopecia areata.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Systemic corticosteroids can cause unusual skin issues in people with juvenile rheumatoid arthritis.

Most people with alopecia areata have nail changes, which are common but don't greatly affect their quality of life.

A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.

Both androgenetic alopecia and alopecia areata negatively impact quality of life, with no significant difference between them.

A(1-7) treatment reduces symptoms of lupus in mice.

Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.

Switching from infliximab to Ustekinumab improved both hair loss and Crohn's symptoms in the patient.